Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Comparison of immune checkpoint inhibitor plus chemothera... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1%–49%): TOPGAN2023-01
0
Authors
Hisashi Tanaka
19 more
Hisashi Tanaka
•
Tomonori Makiguchi
17 more
•
Makoto Nishio
Published
November 1, 2024
Paper
Conversation
0
Reviews
0
Bounties
0
Abstract
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
European Journal of Cancer
Topics
Medicine
Cancer Oncology
Internal Medicine
Surgery
Nivolumab
Show all topics
DOI
10.1016/j.ejca.2024.115117
License
CC-BY
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
European Journal of Cancer
Topics
Medicine
Cancer Oncology
Internal Medicine
Surgery
Nivolumab
Show all topics
DOI
10.1016/j.ejca.2024.115117
License
CC-BY
